1
|
Geldof J, Truyens M, Hanssens M, Van Gucht E, Holvoet T, Elorza A, Bouillon V, Barros S, Martins V, Argyriou K, Potamianos S, Diculescu M, Stroie T, Bossuyt P, Moens A, Theodoraki E, Koutroubakis IE, Pedro J, Fernandes S, Nikolaou P, Karmiris K, Baert FJ, Ferreiro-Iglesias R, Peeters H, Claeys S, Casanova MJ, Eder P, Porter RJ, Arnott I, Karakan T, Mesonero F, Revés J, Van Dyck E, Jauregui-Amezaga A, Mañosa M, Rivière P, Marquez Mosquera L, Portela F, Pimentel R, Lobaton T. Prophylactic versus endoscopy-driven treatment of Crohn's postoperative recurrence: A retrospective, multicentric European study (PORCSE study). J Crohns Colitis 2024:jjae011. [PMID: 38243807 DOI: 10.1093/ecco-jcc/jjae011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Indexed: 01/22/2024]
Abstract
BACKGROUND AND AIMS No consensus exists on optimal strategy to prevent postoperative recurrence (POR) after ileocecal resection (ICR) for Crohn's disease (CD).We compared early medical prophylaxis versus expectant management with treatment driven by findings at elective endoscopy 6-12 months after ICR. METHODS A retrospective, multicentric, observational study was performed. CD-patients undergoing first ICR were assigned to cohort1 if a biologic or immunomodulator was (re)started prophylactically after ICR, or to cohort2 if no postoperative prophylaxis was given and treatment was started as reaction to elective endoscopic findings. Primary endpoint was rate of endoscopic POR (Rutgeerts>i1). Secondary endpoints were severe endoscopic POR (Rutgeerts i3/i4), clinical POR, surgical POR and treatment burden during follow-up. RESULTS Of 346 included patients, 47.4% received prophylactic postoperative treatment (proactive/cohort1) and 52.6% did not (reactive/cohort2).Endoscopic POR (Rutgeerts>i1) rate was significantly higher in cohort2 (41.5% vs 53.8%, OR1.81, P=0.039) at endoscopy 6-12 months after surgery. No significant difference in severe endoscopic POR was found (OR1.29, P=0.517). Cohort2 had significantly higher clinical POR rates (17.7% vs 35.7%, OR3.05, P=0.002) and numerically higher surgical recurrence rates (6.7% vs 13.2%, OR2.59, P=0.051). Cox proportional hazards regression analysis showed no significant difference in time to surgical POR of proactive versus expectant/reactive approach (HR2.50, P=0.057). Quasi-Poisson regression revealed a significantly lower treatment burden for immunomodulator use in cohort2 (mean ratio 0.53, P=0.002), but no difference in burden of biologics or combination treatment. CONCLUSIONS The PORCSE study showed lower rates of endoscopic POR with early postoperative medical treatment compared to expectant management after first ileocecal resection for Crohn's disease.
Collapse
Affiliation(s)
- Jeroen Geldof
- Department of Gastroenterology and Hepatology, University Hospital Ghent, Ghent, Belgium
| | - Marie Truyens
- Department of Gastroenterology and Hepatology, University Hospital Ghent, Ghent, Belgium
| | - Michiel Hanssens
- Department of Gastroenterology and Hepatology, University Hospital Ghent, Ghent, Belgium
| | - Emily Van Gucht
- Department of Gastroenterology and Hepatology, University Hospital Ghent, Ghent, Belgium
| | - Tom Holvoet
- Department of Gastroenterology and Hepatology, VITAZ, Sint-Niklaas, Belgium
| | - Ainara Elorza
- Department of Gastroenterology, Hospital Universitario de Galdakao, Biocruces Bizkaia Health Research Institute, Vizcaya, Spain
| | - Vincent Bouillon
- Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
| | - Sónia Barros
- Department of Gastroenterology - Algarve Universitary Medical Center, Portugal
| | - Viviana Martins
- Department of Gastroenterology - Algarve Universitary Medical Center, Portugal
| | - Konstantinos Argyriou
- University Hospital of Larisa - IBD unit, Department of Gastroenterology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece
| | - Spyridon Potamianos
- University Hospital of Larisa - IBD unit, Department of Gastroenterology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece
| | - Mircea Diculescu
- Gastroenterology and Hepatology Center Fundeni Clinical Institute, Carol Davila University of Medicine Bucharest, Bucharest, Romania
| | - Tudor Stroie
- Gastroenterology and Hepatology Center Fundeni Clinical Institute, Carol Davila University of Medicine Bucharest, Bucharest, Romania
| | - Peter Bossuyt
- Imelda GI clinical research center, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium
| | - Annick Moens
- Imelda GI clinical research center, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium
| | - Eirini Theodoraki
- Department of Gastroenterology, University Hospital Heraklion, Heraklion, Greece
| | | | - Juliana Pedro
- Department of Gastroenterology and Hepatology, Hospital Santa Maria, Centro Hospital Universitario de Liboa Norte, Lisbon, Portugal
| | - Samuel Fernandes
- Department of Gastroenterology and Hepatology, Hospital Santa Maria, Centro Hospital Universitario de Liboa Norte, Lisbon, Portugal
| | | | | | - Filip J Baert
- Department of Gastroenterology, AZ Delta, Roeselare, Belgium
| | - Rocio Ferreiro-Iglesias
- Inflammatory Bowel Diseases Unit, Department of Gastroenterology, Hospital Clinico Universitario de Santiago, Fundación Instituto de investigación Sanitaria de Santiago de Compostela, Galicia, Spain
| | - Harald Peeters
- Department of Gastroenterology, AZ Sint-Lucas, Ghent, Belgium
| | - Sophie Claeys
- Department of Gastroenterology, AZ Sint-Lucas, Ghent, Belgium
| | - Mariá José Casanova
- Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | - Piotr Eder
- Department of Gastroenterology, Dietetics and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland
| | - Ross J Porter
- Edinburgh IBD unit, Western General Hospital, NHS Lothian - Edinburgh, Edinburgh, Scotland
| | - Ian Arnott
- Edinburgh IBD unit, Western General Hospital, NHS Lothian - Edinburgh, Edinburgh, Scotland
| | | | - Francisco Mesonero
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramon y Cajal, Spain
| | - Joana Revés
- Department of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal
| | - Evi Van Dyck
- Department of Gastroenterology, AZ Klina, Brasschaat, Belgium
| | - Aranzazu Jauregui-Amezaga
- Department of Gastroenterology and Hepatology, University Hospital Antwerp, Belgium. Laboratory of Experimental Medicine and Pediatrics (LEMP), Division of Gastroenterology-Hepatology, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
| | - Míriam Mañosa
- Centro de Investigacion Biomédica en Red de Enfermedades Hepaticas y Digestivas CIBERehd. Hospital Department of Gastroenterology and Hepatology, Universitario Germans Trias i Pujol, Barcelona, Spain
| | - Pauline Rivière
- Department of Hepato-Gastroenterology and digestive oncology, CHU Bordeaux, Hôpital Haut Levêque, Bordeaux, France
| | | | - Francisco Portela
- Department of Gastroenterology, Hospital and University of Coimbra, Portugal
| | - Raquel Pimentel
- Department of Gastroenterology, Hospital and University of Coimbra, Portugal
| | - Triana Lobaton
- Department of Gastroenterology and Hepatology, University Hospital Ghent, Ghent, Belgium
| |
Collapse
|
2
|
Preda CM, Istratescu D, Nitescu M, Manuc T, Manuc M, Stroie T, Catrinoiu M, Tieranu C, Meianu CG, Tugui L, Ciora CA, Louis E, Diculescu M. Impact of Dietary Patterns in Inflammatory Bowel Disease Subtypes Versus Healthy Subjects: a Retrospective Cohort Study. Maedica (Bucur) 2023; 18:174-181. [PMID: 37588829 PMCID: PMC10427093 DOI: 10.26574/maedica.2023.18.2.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 08/18/2023]
Abstract
Objectives:Inflammatory bowel diseases (IBD) have been associated with multiple environmental factors, including diet. A dietary pattern characterized by low fiber content, high fat content and high carbohydrate content has been linked to the development of IBD. The objective of the current investigation is to examine the potential link between dietary patterns and the occurrence of IBD and to investigate whether there are any differences in relation to the type of IBD and specific food groups. Material and methods:We conducted an observational retrospective comparative study using three cohorts: 89 Crohn's disease (CD) patients, 40 ulcerative colitis (UC) patients and 64 healthy subjects. All participants underwent structured interviews and were required to complete a questionnaire regarding their dietary habits either prior to the onset of IBD or within the last year for control subjects. Results:A higher proportion of CD patients reported a higher rate of salt intake (71.9% vs. 53.1%, p-value = 0.043), sweetened beverages (38.2% vs. 17.2%, p-value=0.022), processed meat (66.3% vs. 40.6%, p-value=0.007), fatty meat (50.6% vs. 28.1%, p-value=0.021), fried foods (47.2% vs. 9.4%, p-value<0.001) and mayonnaise (21.3% vs. 6.2%, p-value=0.032) and a lower intake of nuts and seeds (20.2% vs. 43.8%, p-value=0.004) and yogurt (23.6% vs. 43.8%, p-value=0.030) compared to healthy subjects. Compared to controls, in the UC group there was a higher consumption of salt (85% vs. 53.1%, p-value=0.003), sweetened beverages (47.5% vs. 17.2%, p-value=0.005), fatty meat (55% vs. 28.1%, p-value=0.025) and fried foods (55% vs. 9.4%, p-value<0.001) and a lower intake of nuts and seeds (10% vs. 43.8%, p-value=0.001). Conclusion:Diet patterns before the onset of the disease are similar in patients with Crohn's disease and patients with ulcerative colitis: increased consumption of sweetened beverages, processed and fatty meat, fried food, salt, store-bought ice cream, and mayonnaise, and decreased intake of seeds, nuts, and yogurt.
Collapse
Affiliation(s)
- Carmen Monica Preda
- "Carol Davila" Gastroenterology & Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Doina Istratescu
- Department of Gastroenterology, Fundeni Clinical Institute, Bucharest, Romania
| | - Maria Nitescu
- "Carol Davila" University of Medicine and Pharmacy, "Prof. Dr. Matei Bals" National Institute for Infectious Diseases, Bucharest, Romania
| | - Teodora Manuc
- "Carol Davila" Gastroenterology & Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Mircea Manuc
- "Carol Davila" Gastroenterology & Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Tudor Stroie
- "Carol Davila" Gastroenterology & Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Mihai Catrinoiu
- "Carol Davila" Gastroenterology & Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Cristian Tieranu
- Elias Emergency Hospital, Gastroenterology & Hepatology Department, Bucharest, Romania
| | - Corina Gabriela Meianu
- "Carol Davila" Gastroenterology & Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Letitia Tugui
- Department of Gastroenterology, Fundeni Clinical Institute, Bucharest, Romania
| | | | - Edouard Louis
- Department of Gastroenterology, University Hospital CHU Liège, Belgium
| | - Mircea Diculescu
- "Carol Davila" Gastroenterology & Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania
| |
Collapse
|
3
|
Stroie T, Preda C, Istratescu D, Ciora C, Croitoru A, Diculescu M. Anxiety and depression in patients with inactive inflammatory bowel disease: The role of fatigue and health-related quality of life. Medicine (Baltimore) 2023; 102:e33713. [PMID: 37171347 PMCID: PMC10174368 DOI: 10.1097/md.0000000000033713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/13/2023] Open
Abstract
Inflammatory bowel diseases (IBD) are chronic conditions characterized by a remitting-relapsing course. Patients with IBD have an impaired quality of life and are more often affected by anxiety and depression. This study aimed to evaluate the prevalence and severity of anxiety and depression in patients with inactive IBD, and to identify factors associated with them. A total of 132 consecutive patients diagnosed with IBD for over 3 months that were in corticosteroid-free remission at the time of assessment were enrolled in this observational, cross-sectional study. Anxiety, depression, fatigue, and health-related quality of life (HR-QoL) were evaluated using the following self-administered questionnaires: HADS, Functional Assessment of Chronic Illness Therapy-Fatigue, and IBDQ 32. Symptoms of anxiety and depression were considered for HADS-A > 7 points and HADS-D > 7 points, respectively. Out of the 132 patients included, 76 (57.6%) were men. The median patient age was 38 years (interquartile range 30-47). Eighty-three patients (62.9%) were diagnosed with Crohn disease, and 49 (37.1%) with ulcerative colitis. Most of the patients were treated with biologics (85.6%). Anxiety was identified in 34.1% of patients, and two thirds of them (68.9%) had mild symptoms. A lower proportion of patients were presenting symptoms of depression (18.2%), the vast majority (91.7%) having mild forms. In the multivariate analysis, anxiety was significantly associated with fatigue [odds ratio (OR) 4.39, 95% confidence interval (CI): 1.22-15.79, P = .02] and lower HR-QoL (OR 2.46, 95% CI: 1.70-3.91, P < .001), while depression was associated with exposure to multiple biologics (OR 3.33, 95% CI: 1.01-10.97, P = .04) and fatigue (OR 9.70, 95% CI: 1.67-56.27, P = .01). In conclusion, anxiety and depression are highly prevalent in patients with IBD even during the periods of remission. Both anxiety and depression are associated with fatigue. In addition, lower HR-QoL is associated with anxiety and exposure to multiple biologics with depression.
Collapse
Affiliation(s)
- Tudor Stroie
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Carmen Preda
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Doina Istratescu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Cosmin Ciora
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Adina Croitoru
- "Titu Maiorescu" University, Bucharest, Romania
- Oncology Department, Fundeni Clinical Institute, Bucharest, Romania
| | - Mircea Diculescu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, Bucharest, Romania
| |
Collapse
|
4
|
Stroie T, Preda C, Meianu C, Istrătescu D, Manuc M, Croitoru A, Gheorghe L, Gheorghe C, Diculescu M. Fatigue Is Associated with Anxiety and Lower Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Remission. Medicina (B Aires) 2023; 59:medicina59030532. [PMID: 36984533 PMCID: PMC10058711 DOI: 10.3390/medicina59030532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Revised: 03/04/2023] [Accepted: 03/07/2023] [Indexed: 03/11/2023] Open
Abstract
Background and Objectives: Inflammatory bowel diseases (IBD) are chronic conditions with an unpredictable course and a remitting–relapsing evolution. Fatigue is a frequent complaint in patients with IBD, affecting approximately half of the newly diagnosed patients with IBD. The aim of this study was to analyze fatigue in patients with IBD in remission. Materials and Methods: One hundred nineteen consecutive outpatients diagnosed with IBD for over 3 months that were in corticosteroid-free clinical and biochemical remission at the time of assessment were included in this cross-sectional study. Out of them, 72 (60.5%) were male; the median age was 39 years (IQR 30–47). Seventy-seven patients (64.7%) were diagnosed with Crohn’s disease and forty-two (35.3%) with ulcerative colitis, with a median disease duration of 6 years (IQR 2–10). Fatigue, health-related quality of life (HR-QoL), anxiety and depression were evaluated using the following self-administered questionnaires: FACIT Fatigue, IBDQ 32 and HADS. Results: The mean FACIT-Fatigue score was 41.6 (SD ± 8.62), and 38.7% of patients were revealed as experiencing fatigue when a cut-off value of 40 points was used. The mean IBDQ 32 score was 189.4 (SD ± 24.1). Symptoms of anxiety and depression were detected in 37% and 21% of the patients, respectively. In the multivariate analysis, fatigue was significantly associated with lower HR-QoL (OR 2.21, 95% CI: 1.42–3.44, p < 0.001), symptoms of anxiety (OR 5.04, 95% CI: 1.20–21.22, p = 0.008), female sex (OR 3.32, 95% CI: 1.02–10.76, p = 0.04) and longer disease duration (OR 1.13, 95% CI: 1.01–1.27, p = 0.04). Conclusions: Fatigue is highly prevalent even in patients with inactive IBD and is correlated with lower HR-QoL and anxiety, as well as with clinical factors such as longer disease duration and female sex.
Collapse
Affiliation(s)
- Tudor Stroie
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Correspondence:
| | - Carmen Preda
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Corina Meianu
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Doina Istrătescu
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mircea Manuc
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Adina Croitoru
- Faculty of Medicine, Titu Maiorescu University, 040441 Bucharest, Romania
- Oncology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Liana Gheorghe
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Cristian Gheorghe
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mircea Diculescu
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Gastroenterology Department, Fundeni Clinical Institute, 022328 Bucharest, Romania
| |
Collapse
|
5
|
Maruntelu I, Preda CM, Sandra I, Istratescu D, Chifulescu AE, Manuc M, Diculescu M, Talangescu A, Tugui L, Manuc T, Stroie T, Andrei AC, Tieranu C, Constantinescu I. HLA Genotyping in Romanian Adult Patients with Celiac Disease, their First-degree Relatives and Healthy Persons. J Gastrointestin Liver Dis 2022; 31:191-197. [PMID: 35694992 DOI: 10.15403/jgld-4187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Accepted: 05/27/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND AND AIMS Celiac disease is characterized by an inappropriate T-cell-mediated response to gluten in small bowel in genetically predisposed individuals, carriers of the DQ2 and/or DQ8 haplotypes of the human leukocyte antigen. The aim of our study was to asses HLA typing in adult patients with celiac disease, in their first degree relatives and in a healthy control group. METHODS We conducted a prospective observational study on three cohorts: 117 patients diagnosed with celiac disease, 41 first-degree relatives of celiac patients and 57 asymptomatic healthy volunteers. Low resolution HLA typing for DQ alleles was performed in all study subjects with DNA extracted from peripheral blood, using SSP HLA-DQB1 kit (Innotrain Diagnostik GmbH, Germany). Next Generation Sequencing (NGS) was used only in 18 patients for typing confirmation of DQB1 and DQA1 loci and whole gene sequencing. RESULTS Prevalence of HLA-DQ2 was significantly higher in the CD group compared to the healthy subjects group (95.6% vs 29.8%, p <0.001), with no statistically significant differences in HLA-DQ8 and combined HLA-DQ2/DQ8 prevalences.Several HLA DQA1 and DQB1 alleles (HLA-DQA1* 05:01, HLA-DQB1*02:01, HLA-DQB1*02:02) and haplotypes (DQA1*02:01-DQB1*02:02,DQA1*05:01-DQB1*02:01) were strongly associated with celiac disease in our group: OR 4.28, 4.28, 4.67 and 5.43 and 4.28 respectively. Predominantly, patients presented with typical symptoms and iron deficiency anemia. 95.5% of them had histological Marsh type modifications ≥3a. A relatively poor response to gluten-free diet was observed and 9.4% developed complications (refractory celiac disease, enteropathy-associated T cell lymphoma, intestinal adenocarcinoma), with a death rate of 6.8%. 23% associated other autoimmune diseases.Screening adherence for 1st degree relatives was very low: only 16%. Familial screening diagnosed 4 cases of asymptomatic celiac disease. 32 relatives (78%) had HLA-DQ2 haplotype, 5 carried HLA-DQ8, 4 didn't carry any risk haplotype. CONCLUSIONS This study demonstrated a higher prevalence of the HLA-DQ2 genotype in patients with celiac disease compared to the healthy population but not of HLA-DQ8 or combined HLA-DQ2/DQ8. Alleles HLA-DQA1* 05:01, HLA-DQB1*02:01, HLA-DQB1*02:02 and haplotypes (DQA1*02:01-DQB1*02:02,DQA1*05:01-DQB1*02:01) were strongly associated with celiac disease in our cohort.
Collapse
Affiliation(s)
- Ion Maruntelu
- Carol Davila University of Medicine and Pharmacy, Centre of Immunogenetics and Virology, Clinical Fundeni Institute, Bucharest, Romania. .
| | - Carmen Monica Preda
- Carol Davila University of Medicine and Pharmacy, Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania. .
| | - Irina Sandra
- Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania.
| | - Doina Istratescu
- Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania.
| | | | - Mircea Manuc
- Carol Davila University of Medicine and Pharmacy, Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania.
| | - Mircea Diculescu
- Carol Davila University of Medicine and Pharmacy, Centre of Immunogenetics and Virology, Clinical Fundeni Institute, Bucharest, Romania.
| | - Adriana Talangescu
- Carol Davila University of Medicine and Pharmacy, Centre of Immunogenetics and Virology, Clinical Fundeni Institute, Bucharest, Romania.
| | - Letitia Tugui
- Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania.
| | - Teodora Manuc
- Carol Davila University of Medicine and Pharmacy, Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania.
| | - Tudor Stroie
- Carol Davila University of Medicine and Pharmacy, Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania.
| | - Adriana Corina Andrei
- Gastroenterology and Hepatology Department, Clinical Fundeni Institute, Bucharest, Romania.
| | - Cristian Tieranu
- Carol Davila University of Medicine and Pharmacy, Gastroenterology and Hepatology Department, Elias Emergency Hospital, Bucharest, Romania.
| | - Ileana Constantinescu
- Carol Davila University of Medicine and Pharmacy, Centre of Immunogenetics and Virology, Clinical Fundeni Institute, Bucharest, Romania.
| |
Collapse
|
6
|
Stroie T, Preda C, Meianu C, Croitoru A, Gheorghe L, Gheorghe C, Diculescu M. Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Clinical Remission: What Should We Look For? Medicina (Kaunas) 2022; 58:medicina58040486. [PMID: 35454325 PMCID: PMC9028218 DOI: 10.3390/medicina58040486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Revised: 03/20/2022] [Accepted: 03/25/2022] [Indexed: 12/07/2022]
Abstract
Background and Objectives: Inflammatory bowel diseases (IBD) are chronic conditions with an unpredictable evolution that can have a negative impact on patients’ quality of life (QoL). Even though patients in remission have a better QoL compared to patients with active disease, they still have a lower QoL compared to healthy people. The aim of this study is to identify the factors that are associated with a lower QoL in patients with IBD in clinical remission, in a tertiary IBD center in Romania. Materials and Methods: Ninety-seven adult patients with a current diagnosis of IBD for over 3 months who were in clinical remission were enrolled in this study. Pregnant women, patients with ostomy, perianal disease, extraintestinal manifestations or other significant comorbidities were excluded. Out of the 97 patients, 63.9% were men. The median age was 39 years (IQR 29−47), and the median disease duration was 5 years (IQR 2−10). Disease activity was assessed using the SCCAI score for ulcerative colitis and HBI score for Crohn’s disease. Remission was defined for SCCAI score ≤ 1 and HBI score ≤ 4. The health-related quality of life (HR-QoL) was assessed using the IBDQ32 score. FACIT-Fatigue was used to evaluate the level of fatigue. Patients with symptoms of anxiety or depression were identified with the HADS score. Symptoms of anxiety were considered when HADS-A >7 points and symptoms of depression when HADS-D >7 points. Results: Sixty-five patients (67%) were diagnosed with CD and the remaining 32 (33%) with UC. Ninety-three patients (95.9%) were on biological therapy. The mean IBDQ score (total score) was 190.54 points (SD +/− 8.2). The mean FACIT Fatigue score was 42.5 (SD +/− 8.2), with 6.2% of patients suffering from severe fatigue (FACIT Fatigue < 30 points). A total of 33% of patients had symptoms of anxiety and 16.5% of depression. Exposure to more than one biologic therapy (p = 0.02), fatigue (p < 0.001) and symptoms of anxiety (p < 0.001) were associated with a lower HR-QoL in the multivariate analysis. Female patients, patients with Crohn’s disease, patients with anemia and patients with symptoms of depression also had a lower HR-QoL, but this did not reach statistical significance in our study. Conclusions: Exposure to a higher number of biological agents (patients that switched multiple biologics), the presence of fatigue and symptoms of anxiety impair the HR-QoL of patients with IBD in clinical remission. Further studies should assess in a prospective manner whether early identification of these factors with prompt clinical interventions could lead to a better HR-QoL in these patients.
Collapse
Affiliation(s)
- Tudor Stroie
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Correspondence:
| | - Carmen Preda
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Corina Meianu
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Adina Croitoru
- Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania;
- Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Liana Gheorghe
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Cristian Gheorghe
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mircea Diculescu
- Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (C.P.); (C.M.); (L.G.); (C.G.); (M.D.)
- Department of Gastroenterology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| |
Collapse
|
7
|
Dumitrascu DL, Baban A, Bancila I, Barboi O, Bataga S, Chira A, Chirila I, Cijevschi Prelipcean C, Ciobanu L, Cozma-Petrut A, David L, Diculescu M, Dobru D, Dimitriu A, Dumitru E, Fadgyas-Stanculete M, Gheorghe C, Gilca-Blanariu GE, Goldis A, Grad S, Macarie M, Marica-Sabo C, Miere D, Nedelcu L, Negovan A, Pojoga C, Pop AV, Popa SL, Porr PJ, Rusu F, Seicean A, Sporea I, Stroie T, Blaga-Surdea T, Tocia C, Trifan A, Brisc C, Drug V. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis 2021; 30:291-306. [PMID: 33951120 DOI: 10.15403/jgld-3581] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND AIMS The nonpharmacological therapy in irritable bowel syndrome (IBS) is expanding rapidly. Practitioners and medical educators need to be aware of progress and changes in knowledge of this topic. The Romanian Society of Neurogastroenterology aimed to create guidelines based on best evidence on the use of nonpharmacological therapy in IBS. METHODS A group of experts was constituted. This was divided in eleven subgroups dedicated to eleven categories of nonpharmacological therapy. The subgroups searched the literature and formulated statements and recommendations. These were submitted to vote in order to obtain consensus. RESULTS The outcome of this activity is represented by the guidelines of the Romanian Society of Neurogastroenterology, presented in this paper. The recommendations are seen as complementary to the pharmacological therapy and are not intended to recommend avoiding pharmacological drugs. CONCLUSIONS These guidelines were elaborated by a Delphi process and represent a useful tool for physicians managing patients with IBS.
Collapse
Affiliation(s)
- Dan L Dumitrascu
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Department of Internal Medicine, Cluj-Napoca, Romania. .
| | - Adriana Baban
- Dept. of Psychology; Babes-Bolyai University, Cluj-Napoca, Romania.
| | - Ion Bancila
- Center of Gastroenterology and Hepatology Fundeni Clinical Institute, Bucharest, Romania.
| | - Oana Barboi
- Institute of Gastroenterology and Hepatology, Iasi; Grrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
| | - Simona Bataga
- George E. Palade University of Medicine, Pharmacy, Sciences and Tehnology, Tg. Mures, Romania.
| | - Alexandra Chira
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Department of Internal Medicine, Cluj-Napoca, Romania.
| | - Ioan Chirila
- Gheorghe T. Popa University of Medicine and Pharmacy, Iasi; Deptartment of Environmental Health, National Institute of Public Health - RCoPH Iasi, Romania.
| | - Cristina Cijevschi Prelipcean
- Institute of Gastroenterology and Hepatology, Iasi; Grrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
| | - Lidia Ciobanu
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
| | - Anamaria Cozma-Petrut
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; Deptartment of Bromatol, Hygiene, Nutrition, Romania.
| | - Liliana David
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; Deptartment of Nursing, Romania.
| | - Mircea Diculescu
- Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy Bucharest, Romania.
| | - Daniela Dobru
- George E. Palade University of Medicine, Pharmacy, Sciences and Tehnology, Tg. Mures, Romania.
| | - Anca Dimitriu
- Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy Bucharest, Romania.
| | - Eugen Dumitru
- Research Center for the Morphological and Genetic Study in Malignant Pathology; Faculty of Medicine, Ovidius University Constanța, Romania.
| | - Mihaela Fadgyas-Stanculete
- Iuliu Hatieganu Univeristy of Medicine and Pharmacy, Cluj-Napoca; Department of Neurosciences, Cluj-Napoca, Romania.
| | - Cristian Gheorghe
- Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy Bucharest, Romania.
| | | | - Adrian Goldis
- Department of Gastroenterology and Hepatology Victor Babeș University of Medicine and Pharmacy, Academy of Medicale Science, Research Center, Timișoara, Romania.
| | - Simona Grad
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Department of Internal Medicine, Cluj-Napoca, Romania.
| | - Melania Macarie
- George E. Palade University of Medicine, Pharmacy, Sciences and Tehnology, Tg. Mures, Romania.
| | - Cristina Marica-Sabo
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Dept. of Internal Medicine, Cluj-Napoca, Romania.
| | - Doina Miere
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; Deptartment of Bromatol, Hygiene, Nutrition, Romania.
| | | | - Anca Negovan
- George E. Palade University of Medicine, Pharmacy, Sciences and Tehnology, Tg. Mures, Romania.
| | - Cristina Pojoga
- Babes-Bolyai University, Cluj-Napoca; Regional Institute of Gastroenterol and Hepatol, Cluj-Napoca; Department of Clinical Psychology and Psychotherapy, International Institute for Advanced Study of Psychotherapy and Applied Mental Health, Cluj-Napoca; Romania.
| | - Andrei Vasile Pop
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Department of Internal Medicine, Cluj-Napoca, Romania.
| | - Stefan-Lucian Popa
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Department of Internal Medicine, Cluj-Napoca, Romania.
| | | | - Flaviu Rusu
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Department of Internal Medicine, Cluj-Napoca, Romania.
| | - Andrada Seicean
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
| | - Ioan Sporea
- Department of Gastroenterology and Hepatology, Victor Babeș University of Medicine and Pharmacy, Academy of Medical Science, Research Center, Timișoara, Romania.
| | - Tudor Stroie
- Center of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy Bucharest, Romania.
| | - Teodora Blaga-Surdea
- Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca; 2nd Department of Internal Medicine, Cluj-Napoca, Romania.
| | - Cristina Tocia
- Faculty of Medicine, Ovidius University Constanța, Romania.
| | - Anca Trifan
- Institute of Gastroenterology and Hepatology, Iasi; Grrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
| | - Ciprian Brisc
- Faculty of Medicine and Pharmacy, University of Oradea, Romania.
| | - Vasile Drug
- Institute of Gastroenterology and Hepatology, Iasi; Grrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
| |
Collapse
|
8
|
Manuc M, Preda CM, Iliescu L, Istratescu D, Chifulescu AE, Pop CS, Trifan A, Stanciu C, Popescu CP, Diculescu MM, Manuc T, Tugui L, Cianga E, Tieranu CG, Stroie T, Gheorghe LS. Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1B. Ro J Infect Dis 2021; 24:44-50. [DOI: 10.37897/rjid.2021.1.6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/14/2023] Open
Abstract
Background and aims. For the 8-week OPrD regimen, real world data are insufficient. This study aims to compare the efficacy of the two types of regimens (12-week versus 8-week) in a real world cohort of patients with genotype 1b. Material and methods. We analysed a multicentric retrospective cohort enrolling 1436 patients who started HCV therapy in 2018-2019. Liver fibrosis was staged in all subjects by Fibromax. Efficacy was assessed by the percentage of patients achieving SVR 12 weeks post-treatment (SVR12). Results. Out of the 1436 analysed patients, 112 received 8 weeks therapy and 1324 received 12 weeks. In this cohort the proportion of male patients was 25.2%, the median age 61 years, 28.2% were interferon pre-treated, and the rate of co-morbidities was 47%. 42% of the subjects had F2 fibrosis, 29% F1 fibrosis, 16% F3 and 12% F4. The SVR rate was comparable in both groups of patients (97% in those treated with OPrD 12 weeks vs 96.4% in those that received OPrD 8 weeks) (by intention-to-treat). In the 12 weeks arm, the drop-out rate was 0.8% and the rate of severe adverse events was 1%, while in the arm of 8 weeks therapy there were no severe adverse events reported and no drop-out (p = 0.25). The only predictive factor for non-response in both treatment arms was the male sex. Conclusions. OPrD 8 weeks proved to be highly efficient in our patients with a 96.4% SVR. No serious adverse events and no drop out were reported.
Collapse
|
9
|
Vadan R, Iacob R, Costache R, Stroie T, Saizu IA, Iacob S, Gheorghe L, Diculescu M, Gheorghe C. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic. J Gastrointestin Liver Dis 2020; 29:549-553. [PMID: 33331349 DOI: 10.15403/jgld-3183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Accepted: 12/03/2020] [Indexed: 11/01/2022]
Abstract
BACKGROUND AND AIMS Inflammatory bowel diseases (IBD) patients management has been challenging during the ongoing coronavirus disease 2019 (COVID-19) pandemic, due to lockdowns, limitation of access to medical facilities and new recommendations regarding patient management. The implications of the COVID-19 pandemic on IBD patients' management were assessed in our Tertiary Gastroenterology Center in Bucharest, Romania. METHODS Medical records of IBD patients admitted between 15th of March and 15th of August 2020 were retrospectively reviewed and compared to a control cohort of consecutive IBD patients admitted to our unit during the corresponding period of 2019. RESULTS There was a highly significant shift towards one-day hospitalization during the referral period in 2020 for IBD cases (91% in 2020 vs 82.2% in 2019, p=0.0001). There was no statistically significant difference between the distribution of patient's gender, IBD phenotype or newly diagnosed IBD cases. A significantly lower proportion of admitted patients received 5-aminosalicylic acid (29% vs 41.2%, p=0.0001), whereas a substantially higher number of patients were prescribed biological therapy in 2020 in comparison to the corresponding 2019-time frame (79.5% vs 57.9%, p<0.0001). The distribution of the biological agent used was significantly different in 2019 in comparison to the 2020 period mainly due to the increase in vedolizumab prescription in 2020 (p<0.0001). During the study period in 2020, seven IBD patients (1.7%) were diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) infection, all of them with mild symptoms without impact on the IBD course. CONCLUSIONS The COVID-19 pandemic led to reorganizing medical care, limiting the hospital admissions in favor of severe IBD cases, favoring telemedicine for mild disease and optimization of treatment for moderate to severe IBD with an increased use of biologicals aimed to maximize the risk/benefit ratio. Incidence of SARS-Cov2 infection during the first wave of COVID-19 infection in our study group was 1.7% and did not adversely impact the IBD disease course.
Collapse
Affiliation(s)
- Roxana Vadan
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania. .
| | - Razvan Iacob
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. .
| | - Roxana Costache
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania.
| | - Tudor Stroie
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania.
| | - Ionut Adrian Saizu
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania.
| | - Speranta Iacob
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
| | - Liliana Gheorghe
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
| | - Mircea Diculescu
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
| | - Cristian Gheorghe
- Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
| |
Collapse
|